Age 18 years or older; history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement); screening IgE > 200 and/or personal and/or familial history of atopy
For more information, contact Giselle Singer, Clinical Research Program Director, at giselle.singer@mssm.edu or 212-241-3288
This is a prospective, randomized, double blind, placebo-controlled clinical trial. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of atopy (including asthma, atopic dermatitis, allergic rhinitis, food allergy, or eosinophilic esophagitis).
Subjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).
Eligibity criteria:*
* There are additional requirements as determined by a screening process.
